Compare UHT & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHT | ALLO |
|---|---|---|
| Founded | 1986 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.5M | 539.4M |
| IPO Year | 1995 | 2018 |
| Metric | UHT | ALLO |
|---|---|---|
| Price | $40.03 | $2.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $43.00 | $8.35 |
| AVG Volume (30 Days) | 43.3K | ★ 14.6M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.33% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $99,190,000.00 | N/A |
| Revenue This Year | $2.12 | N/A |
| Revenue Next Year | $2.94 | $142,416.42 |
| P/E Ratio | $111.89 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $35.26 | $0.86 |
| 52 Week High | $44.70 | $4.46 |
| Indicator | UHT | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 38.29 | 50.39 |
| Support Level | $39.47 | $2.12 |
| Resistance Level | $41.13 | $2.76 |
| Average True Range (ATR) | 0.82 | 0.12 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 16.45 | 72.73 |
Universal Health Realty Income Trust is a healthcare REIT. The company is engaged in the business of investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. The company actively manages a portfolio of healthcare and human service facilities. The revenue and net income are generated from the operation of the investment portfolio, located throughout the United States.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.